Non Small Cell Lung Cancer
The immune system’s failure to combat cancer can result when tumors evade or suppress immune defenses. Some drugs are designed to counter this by stimulating or enhancing immune reactivity to cancer.
Serametrix has identified a panel of eleven antigens and has developed a microarray-based assay that measures antibodies to each of these eleven antigens in multiplex. Patients with baseline and/or post-treatment immunity to this panel are more likely to have partial or complete response and/or longer survival times following drug treatment. This observation has been repeated in different studies with different drug types.
This assay is now offered to pharmaceutical companies engaged in drug discovery and development. The service includes serum profiling and data reporting for each serum or plasma sample submitted for analysis.
References:  Isobe, M. et al. (2009) Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient, Cancer Immunity, 1 October 2009, Vol. 9:8. Gedye et al (2009) CT antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother 58:1635–1646 Ribas et al (2009) Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? Clin Cancer Res December 1, 2009 15:7116-7118